'Armored' CAR T Cells Highly Active in Lymphoma After Prior CAR-T Failure
(MedPage Today) — A next-generation, anti-CD19 enhanced (or “armored”) CAR T-cell product showed promising efficacy and safety in a phase I trial of lymphoma patients who had previously failed anti-CD19 CAR T-cell therapy.
Among 21 patients…
